•  
  •  
  •  
  •  

2026-08-12 01:09:10

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  LifeSciences

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Varenyam Biolifesciences to upgrade its upcoming Savli facility to offer biologics and biosimilar CDMO services for US, EU and SRA RoW markets
  • Zydus Lifesciences Reports Q1 FY27 Results: Operational Revenue Up 22% to ₹80,170 Million
  • Zydus launches REVAHALE™, India's first once-daily nebulised LAMA for COPD
  • Zydus Lifesciences Ltd receives EIR from the USFDA for its injectable facility with VAI classification
  • Astec LifeSciences Limited Reports Q1 FY27 Results: Net Loss Narrows to ₹1,870.73 Lakh Consolidated
  • RPG Life Sciences Reports Q1 FY27 Results: Consolidated Net Profit Up 17% YoY to ₹30.76 Crore
  • RPG Life Sciences partners with Archerchem Healthcare for Naprosyn ES launch
  • Suven Life Sciences Approves INR 248 Crore Share Allotment, Board Re-appointment, and New Singapore Subsidiary
  • Zydus signs MoU with Apollo Hospitals to expand access to the Shield™ Multi-Cancer Detection test (MCD) in India
  • Zydus Lifesciences and Sunshine Healthcare announce JV to strengthen pharmaceutical manufacturing in Sri Lanka
  • Suven Life Sciences to showcase its Differentiated CNS Clinical Candidates and Partnering Strategies at BIO International Convention 2026, 22-25, June 2026, San Diego, USA
  • Zydus announces the successful completion of acquisition of Assertio Holdings
  • Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107
  • Suven Life Sciences announces three poster presentations on Samelisant (SUVN-G3031), including global Phase-3, AWAKE Narcolepsy Study at SLEEP-2026
  • Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer's Disease
  • Zydus Therapeutics receives USFDA priority review to NDA for Saroglitazar
  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • Zydus Lifesciences Limited Financial Performance for Q4 & Full Year FY26
  • Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer's Dementia
  • Cohance Lifesciences Ltd Q4 FY2025-26 consolidated PAT slides to Rs. 19.55 crores
  • Sai Life Sciences becomes first Indian CRDMO with a site powered by 100% renewable energy
  • Persistent Achieves Databricks Brickbuilder Specialization for Healthcare & Life Sciences, Expanding Production-Ready Data and AI Solutions For Regulated Environments
  • USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad
  • RPG Life Sciences Ltd Q4 FY2025-26 consolidated profit at Rs. 29.90 crores

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025